The bioconvergence market has experienced rapid growth, with predictions of reaching $159.66 billion in 2025 and $243.53 billion in 2029. This growth is fueled by personalized medicine, biomedical engineering advancements, and increased healthcare digitization. Innovative trends like AI in drug discovery and lab-on-a-chip technologies are shaping the industry. Major drivers include the emphasis on personalized medicine and the approval of new personalized medicines by the FDA. Major players in the market include Pfizer, Johnson & Johnson, and Merck. Companies are focusing on innovative solutions like automated miniaturized single-cell proteomics sample preparation, enhancing protein analysis and workflows. The market is segmented by component, technology, application, end-user, devices, software, services, and platforms, with North America leading in 2024 and Asia-Pacific expected to be the fastest-growing region.
Read more from cbinsights.com
